Edwards Lifesciences EW shares soared 6
Edwards Lifesciences EW shares soared 6.3% within the final buying and selling session to shut at $95.24. The transfer was backed by stable quantity with way more shares altering fingers than in a standard session. This compares to the inventory’s 11.2% acquire over the previous 4 weeks.
Edwards Lifesciences scored a powerful value rise pushed by its encouraging first-quarter 2021 outcomes, with adjusted earnings and web gross sales each surpassing the Zacks Consensus Estimate by 14.9% and 4.9%, respectively. The corporate’s raised 2021 adjusted earnings steering that together with better-than-expected Q2 earnings outlook additionally buoy optimism.
Worth and Consensus
This medical gadget maker is predicted to publish quarterly earnings of $0.51 per share in its upcoming report, which represents a year-over-year change of +50%. Revenues are anticipated to be $1.25 billion, up 34.6% from the year-ago quarter.
Earnings and income development expectations definitely give a great sense of the potential power in a inventory, however empirical analysis exhibits that traits in earnings estimate revisions are strongly correlated with near-term inventory value actions.
For Edwards Lifesciences, the consensus EPS estimate for the quarter has remained unchanged over the past 30 days. And a inventory’s value often does not preserve transferring larger within the absence of any pattern in earnings estimate revisions. So, be certain that to keep watch over EW going ahead to see if this latest bounce can flip into extra power down the highway.
The inventory at present carries a Zacks Rank 3 (Maintain). You possibly can see the whole record of at the moment’s Zacks Rank #1 (Robust Purchase) shares right here >>>>
Need the newest suggestions from Zacks Funding Analysis? Right now, you’ll be able to obtain 7 Greatest Shares for the Subsequent 30 Days. Click on to get this free report
Edwards Lifesciences Company (EW): Free Inventory Evaluation Report
To learn this text on Zacks.com click on right here.
Zacks Funding Analysis
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially replicate these of Nasdaq, Inc.